<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2024-4167</article-id><article-id custom-type="edn" pub-id-type="custom">YWNXZD</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-4167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW ARTICLES</subject></subj-group></article-categories><title-group><article-title>Путь эффективной профилактики сердечно-сосудистых осложнений: обзор</article-title><trans-title-group xml:lang="en"><trans-title>The way to effective prevention of cardiovascular complications: review</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1250-8798</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хидирова</surname><given-names>Л. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Khidirova</surname><given-names>L. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хидирова Людмила Даудовна — д.м.н., профессор кафедры фармакологии, клинической фармакологии и доказательной медицины, ведущий кардиолог.</p><p>630091, Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><email xlink:type="simple">h_ludmila73@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-7408-838X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Закорюкина</surname><given-names>С. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zakoryukina</surname><given-names>S. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Закорюкина Светлана Георгиевна — врач-ординатор кафедры терапии, гематологии и трансфузиологии.</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Novosibirsk</p></bio><email xlink:type="simple">ha9n13@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО "Новосибирский государственный медицинский университет" Минздрава России; ГБУЗ Новосибирской области "Новосибирский областной клинический кардиологический диспансер"</institution></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University; Novosibirsk Regional Clinical Cardiology Dispensary</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО "Новосибирский государственный медицинский университет" Минздрава России</institution></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2024</year></pub-date><volume>23</volume><issue>10</issue><fpage>4167</fpage><lpage>4167</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хидирова Л.Д., Закорюкина С.Г., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Хидирова Л.Д., Закорюкина С.Г.</copyright-holder><copyright-holder xml:lang="en">Khidirova L.D., Zakoryukina S.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/4167">https://cardiovascular.elpub.ru/jour/article/view/4167</self-uri><abstract><p>Представлен описательный обзор современной российской и зарубежной литературы, посвященной концепции "полипилл" (комбинации нескольких лекарств в одной таблетке) в клинической практике терапевта и кардиолога.</p><sec><title>Методология</title><p>Методология. При поиске информации использованы материалы следующих баз данных: PubMed, Scopus, Web of Science и Co­chrane Library, а также в российских базах, включая eLIBRARY и КиберЛенинка. В ходе поиска использовались ключевые слова и сочетания, такие как "полипилл", "комбинированная терапия", "сердечно-сосудистые заболевания", "приверженность лечению", "поликомпонентные препараты" и их аналоги на английском и русском языках. Особое внимание уделялось работам, опубликованным за последние 15 лет, с акцентом на исследования, проведенные в течение последних 5 лет, чтобы отразить текущие тенденции и инновации в области применения "полипиллов".</p></sec><sec><title>Результаты</title><p>Результаты. Клинические подтверждения преимуществ фиксированных комбинаций позволяют реализовать стратегию полипилл в условиях реальной клинической практики и добиваться максимального снижения риска сердечно-сосудистых осложнений.</p></sec><sec><title>Заключение</title><p>Заключение. Новые комбинации лекарственных средств уже разработаны и доступны для использования, их необходимо внедрять, чтобы терапия была наиболее адаптированной для многих пациентов и эффективной для достижения разных лечебных задач в клинической практике терапевтов и кардиологов.</p></sec></abstract><trans-abstract xml:lang="en"><p>A descriptive review of modern Russian and foreign literature devoted to the polypill concept in internal medicine and cardiology practice is presented.</p><sec><title>Methodology</title><p>Methodology. The following databases were used in the search for information: PubMed, Scopus, Web of Science and Cochrane Library, as well as Russian databases, including eLIBRARY and CyberLeninka. The search used keywords and phrases such as "polypill", "combination the­rapy", "cardiovascular diseases", "adherence", "polycomponent drugs" and their analogues in English and Russian. Particular attention was paid to studies published over the past 15 years, with an emphasis on studies conducted over the past 5 years to reflect current trends and innovations in the use of polypills.</p></sec><sec><title>Results</title><p>Results. Clinical evidence of the benefits of fixed-dose combinations al­lows the implementation of the polypill strategy in practice and to achieve maximum reduction of cardiovascular risk.</p></sec><sec><title>Conclusion</title><p>Conclusion. Novel drug combinations have already been developed and are available for use. They need to be introduced so that the therapy is most adapted for many patients and effective in achieving different therapeutic goals in internal medicine and cardiology practice.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>дислипидемия</kwd><kwd>полипилл</kwd><kwd>приверженность</kwd><kwd>фиксированные комбинации антигипертензивных препаратов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>dyslipidemia</kwd><kwd>polypill</kwd><kwd>adherence</kwd><kwd>fixed-dose combinations of antihypertensive drugs</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">При поддержке фармацевтической компании KRKA.</funding-statement><funding-statement xml:lang="en">The study was supported by the phar­ma­ceutical company KRKA.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Муромцева Г. А., Концевая А. В., Константинов В. В., и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11. doi:10.15829/1728-8800-2014-6-4-11.</mixed-citation><mixed-citation xml:lang="en">Muromtseva GA, Kontsevaya A, Konstantinov V, et al. Prevalence of risk factors for noncommunicable diseases in the Russian population in 2012-2013. The results of the ESSAY-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14. doi:10.15829/1728-8800-2014-4-4-14.</mixed-citation><mixed-citation xml:lang="en">Boytsov S, Balanova Yu, Shalnova SA, et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population representative studies with 104 million participants. Lancet 2021;398:957-80. doi:10.1016/S0140-6736(21)01330-1.</mixed-citation><mixed-citation xml:lang="en">NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population representative studies with 104 million participants. Lancet 2021;398:957-80. doi:10.1016/S0140-6736(21)01330-1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Medicine. 2013;11(1):177. doi:10.1186/1741-7015-11-177.</mixed-citation><mixed-citation xml:lang="en">Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Medicine. 2013;11(1):177. doi:10.1186/1741-7015-11-177.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelineson cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special-contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw1062017.</mixed-citation><mixed-citation xml:lang="en">Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelineson cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special-contribution of the European Asso­ciation for Cardiovascular Prevention &amp; Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw1062017.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Roth G, Murray K, Nagavi N, et al. Death Cause Collaborator. Global, regional, and national age-specific mortality rates for 282 causes of death in 195 countries and territories in 1980-2017: Systematic analysis of global disease burden research in 2017. Lancet. 2018;392(10159):1736-88. doi:10.1016/s140-6736(18)32203-7.</mixed-citation><mixed-citation xml:lang="en">Roth G, Murray K, Nagavi N, et al. Death Cause Collaborator. Global, regional, and national age-specific mortality rates for 282 causes of death in 195 countries and territories in 1980-2017: Systematic analysis of global disease burden research in 2017. Lancet. 2018;392(10159):1736-88. doi:10.1016/s140-6736(18)32203-7.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ежов М. В., Кухарчук В. В., Сергиенко И. В. и др. Нарушения липидного обмена. Клинические рекомендации. Российский кардиологический журнал. 2023; 28(5):5471. doi:10.15829/1560-4071-2023-5471.</mixed-citation><mixed-citation xml:lang="en">Ezhov MV, Kuharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical guidelines. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Горохова Т. В., Перепеч Н. Б. Возможности применения комбинированной терапии у пациентов c сочетанием артериальной гипертензии и дислипидемии. Российский кардиологический журнал. 2022;27(7):5132. doi:10.15829/1560-4071-2022-5132.</mixed-citation><mixed-citation xml:lang="en">Gorokhova TV, Perepech NB. Potential of combination therapy in patients with hypertension and dyslipidemia. Russian Journal of Cardiology. 2022;27(7):5132. (In Russ.) doi:10.15829/1560-4071-2022-5132.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О. М., Вавилова Т. В., Карпов Ю. А. и др. Резолюция Cовета экспертов по актуальным вопросам применения ацетилсалициловой кислоты с целью первичной профилактики сердечно-сосудистых заболеваний в свете новых научных данных и обновленных клинических рекомендаций. Кардиоваскулярная терапия и профилактика. 2022; 21(12):3487. doi:10.15829/1728-8800-2022-3487.</mixed-citation><mixed-citation xml:lang="en">Drapkina OM, Vavilova TV, Karpov YuA, et al. The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines. Cardiovascular Therapy and Prevention. 2022;21(12):3487. (In Russ.) doi:10.15829/1728-8800-2022-3487.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA. 2015;313:603-15. doi:10.1001/jama.2014.18574.</mixed-citation><mixed-citation xml:lang="en">Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA. 2015;313:603-15. doi:10.1001/jama.2014.18574.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g.3318.</mixed-citation><mixed-citation xml:lang="en">Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g.3318.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Brainin M, Teuschl Y, Martins S. Polypill: Benefits Seen for Stroke and Other Outcomes. Stroke. 2022;53(8):2695-701. doi:10.1161/STROKEAHA.122.037313.</mixed-citation><mixed-citation xml:lang="en">Brainin M, Teuschl Y, Martins S. Polypill: Benefits Seen for Stroke and Other Outcomes. Stroke. 2022;53(8):2695-701. doi:10.1161/STROKEAHA.122.037313.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Matusitz J, Spear J. Effective communication between doctor and patient: an updated examination. Soc Works Field Public Health. 2014;29(3):252-66. doi:10.1080/19371918.2013.776416.</mixed-citation><mixed-citation xml:lang="en">Matusitz J, Spear J. Effective communication between doctor and patient: an updated examination. Soc Works Field Public Health. 2014;29(3):252-66. doi:10.1080/19371918.2013.776416.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. International Polycap Study 3 Investigators. N Engl J Med. 2021;384(3):216-28. doi:10.1056/NEJMoa2028220.</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. International Polycap Study 3 Investigators. N Engl J Med. 2021;384(3):216-28. doi:10.1056/NEJMoa2028220.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Хидирова Л. Д., Яхонтов Д. А., Мадонов П. Г. Оценка приверженности к терапии у коморбидных больных. Артериальная гипертензия. 2023;29(1):109-18. doi:10.18705/1607-419X-2022-28-6-109-118.</mixed-citation><mixed-citation xml:lang="en">Khidirova LD, Yakhontov DA, Madonov PG. Assessment of adhe­rence to therapy in comorbid patients. Arterial hypertension. 2023;29(1):109-18. (In Russ.) doi:10.18705/1607-419X-2022-28-6-109-118.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Лебедев П. А., Гаранин А. А. От низкодозовых фиксированных комбинаций гипотензивных препаратов до мультитаргетной терапии сердечно-сосудистых заболеваний. Рациональная Фармакотерапия в Кардиологии. 2020;16(4):638-43. doi:10.20996/1819-6446-2020-08-03.</mixed-citation><mixed-citation xml:lang="en">Lebedev PA, Garanin AA. From Low-Dose Fixed Combinations for Arterial Hypertension Treatment to Multi-Target Therapy of Cardiovascular Diseases. Rational Pharmacotherapy in Cardiology. 2020;16(4):638-43. (In Russ.) doi:10.20996/1819-6446-2020-08-03.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920-30. doi:10.1177/2047487314530382.</mixed-citation><mixed-citation xml:lang="en">Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preven­tive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920-30. doi:10.1177/2047487314530382.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Кохан Е. В. Артериальная гипертония и гиперхолестеринемия: время анти-"липотензивной" терапии? Рациональная Фармакотерапия в Кардиологии. 2020; 16(5):842-51. doi:10.20996/1819-6446-2020-09-01.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Kohan EV. Arterial'naya gipertoniya i giperholesterinemiya: vremya anti-"lipotenzivnoj" terapii? Rational Pharmacotherapy in Cardiology. 2020;16(5):842-51. (In Russ.) doi:10.20996/1819-6446-2020-09-01.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Гиляревский С. Р., Бенделиани Н. Г., Голшмид М. В. и др. Применение комбинированных препаратов с постоянными дозами антигипертензивных средств как начальная тактика лечения при повышенном уровне артериального давления: доказанные факты и мнение экспертов. Евразийский Кардиологический Журнал. 2021;(2):92-102. doi:10.38109/2225-1685-2021-2-92-102.</mixed-citation><mixed-citation xml:lang="en">Gilyarevskij SR, Bendeliani NG, Golshmid MV, et al. The ap­plication of combined preparations with constant doses of anti­hypertensive drugs as the initial tactics of treatment at high blood pressure level: proven facts and expert’s opinion. Eurasian Heart Journal. 2021;(2):92-102. (In Russ.) doi:10.38109/2225-1685-2021-2-92-102.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Барышникова Г. А., Чорбинская С. А., Степанова И. И. и др. Полипилюля как средство увеличить эффективность лечения пациентов с высоким сердечно-сосудистым риском. Трудный пациент. 2019;7(3):22. doi:10.26442/2075-1753_19.10.13-18.</mixed-citation><mixed-citation xml:lang="en">Baryshnikova GA, Chorbinskaya SA, Stepanova II, et al. Polypillule as a means of effective treatment of patients with high cardiovascular risk. Difficult patient. 2019;7(3):22. (In Russ.) doi:10.26442/2075-1753_19.10.13-18.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Соколова А. А., Напалков Д. А. Опти­мальные терапевтические стратегии у коморбидных пациентов с артериальной гипертензией и дислипидемией: роль фиксированных комбинаций. Российский кардиологический журнал. 2023;28(12):5712. doi:10.15829/1560-4071-2023-5712.</mixed-citation><mixed-citation xml:lang="en">Sokolova AA, Napalkov DA. Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations. Russian Journal of Cardiology. 2023;28(12):5712. (In Russ.) doi:10.15829/1560-4071-2023-5712.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Se­condary Cardiovascular Prevention. SECURE Investigators. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.</mixed-citation><mixed-citation xml:lang="en">Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Se­condary Cardiovascular Prevention. SECURE Investigators. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Конради А. О., Алиева А. С. Артериальная гипертензия и дислипидемия. Параллельный контроль двух факторов риска — роль комбинаций препаратов. Артериальная гипертензия. 2021;27(3):376-83. doi:10.18705/1607-419X-2021-27-3-376-383.</mixed-citation><mixed-citation xml:lang="en">Konradi AO, Alieva AS. Hypertension and dyslipidemia. Pa­rallel risk factor control: role of ﬁxed combination. Arterial Hypertension. 2021;27(3):376-83. (In Russ.) doi:10.18705/1607-419X-2021-27-3-376-383.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Henavi HA, Sharaf MT, Zohaib M. Polypilular therapy in cardiovascular diseases: a meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023;48(8):101735. doi:10.1016/j.cpcardiol.2023.101735.</mixed-citation><mixed-citation xml:lang="en">Henavi HA, Sharaf MT, Zohaib M. Polypilular therapy in cardiovascular diseases: a meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023;48(8):101735. doi:10.1016/j.cpcardiol.2023.101735.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Joseph P, Prem P, Dans A, et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. 2018;206:72-9. doi:10.1016/j.ahj.2018.07.012.</mixed-citation><mixed-citation xml:lang="en">Joseph P, Prem P, Dans A, et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. 2018;206:72-9. doi:10.1016/j.ahj.2018.07.012.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Castellano JM, Sanz G, Peñalvo JL, et al. Polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82. doi:10.1016/j.jacc.2014.08.021.</mixed-citation><mixed-citation xml:lang="en">Castellano JM, Sanz G, Peñalvo JL, et al. Polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82. doi:10.1016/j.jacc.2014.08.021.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Lonn E, Bosch J, Pogue J, et al. HOPE-3 researchers. New approaches to the primary prevention of cardiovascular diseases: the rationale for the HOPE-3 study, design and initial characteristics of the participants. doi:10.1016/j.cjca.2015.07.001.</mixed-citation><mixed-citation xml:lang="en">Lonn E, Bosch J, Pogue J, et al. HOPE-3 researchers. New approaches to the primary prevention of cardiovascular diseases: the rationale for the HOPE-3 study, design and initial characteristics of the participants. doi:10.1016/j.cjca.2015.07.001.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Webster R, Bullen C, Patel А, еt al. The effect of switching to polypill-based therapy on the initial efficacy of the drug: Post-hoc analysis of the SPACE Collaboration dataset. Cardiology. 2017;13:443-7. doi:10.1016/j.ijcard.2017.09.162.</mixed-citation><mixed-citation xml:lang="en">Webster R, Bullen C, Patel А, еt al. The effect of switching to polypill-based therapy on the initial efficacy of the drug: Post-hoc analysis of the SPACE Collaboration dataset. Cardiology. 2017;13:443-7. doi:10.1016/j.ijcard.2017.09.162.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918-29. doi:10.1001/jama.2013.277064.</mixed-citation><mixed-citation xml:lang="en">Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918-29. doi:10.1001/jama.2013.277064.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Selak V, Ellie KR, Krengle S, et al. Treatment adherence with combination therapy (IMPACT): design and protocol of a randomized controlled trial in primary care. Contemp Clin Tests. 2011;32(6):909-15. doi:10.1016/j.cct.2011.07.006.</mixed-citation><mixed-citation xml:lang="en">Selak V, Ellie KR, Krengle S, et al. Treatment adherence with combination therapy (IMPACT): design and protocol of a randomized controlled trial in primary care. Contemp Clin Tests. 2011;32(6):909-15. doi:10.1016/j.cct.2011.07.006.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Liu H, Patel A, Brown A, et al; Vascular Kanyini Collaboration; Research the Kanyini GAP band. Rationale and design of Kanini's recommendations for compliance in the Kanyini-GAP study: a randomized controlled trial of a polypill-based strategy among indigenous and non-indigenous peoples at high risk of cardiovascular disease. BMC Public Health. 2010;5(10):458. doi:10.1186/1471-2458-10-458.</mixed-citation><mixed-citation xml:lang="en">Liu H, Patel A, Brown A, et al; Vascular Kanyini Collaboration; Research the Kanyini GAP band. Rationale and design of Kanini's recommendations for compliance in the Kanyini-GAP study: a randomized controlled trial of a polypill-based strategy among indigenous and non-indigenous peoples at high risk of cardiovascular disease. BMC Public Health. 2010;5(10):458. doi:10.1186/1471-2458-10-458.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж. Д., Конради А. О., Недогода С. В. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786.</mixed-citation><mixed-citation xml:lang="en">Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial'naya gi­pertenziya u vzroslyh. Klinicheskie rekomendacii 2020. Rus­sian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Хидирова Л. Д., Шпа­гина Л. А., Шпагин И. С. и др. Актуальные проблемы фармакотерапии у коморбидных больных артериальной гипертонией и хронической обструктивной болезнью Атмосфера. Новости кардиологии. 2023;1:22-8. doi:10.24412/2076-4189-2023-12838.</mixed-citation><mixed-citation xml:lang="en">Khidirova LD, Shpagina LA, Shpagin IS, et al. Actual problems of pharmacotherapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease. Atmosphere. Car­diology News. 2023;1:22-8. (In Russ.) doi:10.24412/2076-4189-2023-12838.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Абрамов Н. В., Кашталап В. В., Семенихин В. А. Роль политаблетки (полипилл) в лечении хронических сердечно-сосудистых заболеваний. Медицина в Кузбассе. 2024;1:11-4. doi:10.24412/2687-0053-2024-1-11-14.</mixed-citation><mixed-citation xml:lang="en">Аbramov NV, Kashtalap VV, Semenihin VA. The role of polytablets (polypill) in the treatment of chronic cardiovascular diseases. Medicine in Kuzbass. 2024;1:11-4. (In Russ.) doi:10.24412/2687-0053-2024-1-11-14.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
